Medytox Inc. 13D and 13G filings for Evolus, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
2025-02-06 4:16 pm Sale | 2024-12-31 | 13G | Evolus, Inc. EOLS | Medytox Inc. | 2,136,449 3.400% | -1,244,877![]() (-36.82%) | Filing |
2023-10-18 4:17 pm Sale | 2023-10-16 | 13G | Evolus, Inc. EOLS | Medytox Inc. | 3,381,326 5.900% | -3,915,217![]() (-53.66%) | Filing |
2023-02-06 4:12 pm Sale | 2022-12-31 | 13G | Evolus, Inc. EOLS | Medytox Inc. | 7,296,543 12.970% | -167,109![]() (-2.24%) | Filing |
2022-02-08 9:55 pm Purchase | 2021-12-31 | 13G | Evolus, Inc. EOLS | Medytox Inc. | 7,463,652 13.430% | 701,000![]() (+10.37%) | Filing |
2021-03-01 5:22 pm Purchase | 2021-02-18 | 13G | Evolus, Inc. EOLS | Medytox Inc. | 6,762,652 16.700% | 6,762,652![]() (New Position) | Filing |